These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Carfilzomib: A cause of drug associated thrombotic microangiopathy. Qaqish I; Schlam IM; Chakkera HA; Fonseca R; Adamski J Transfus Apher Sci; 2016 Jun; 54(3):401-4. PubMed ID: 27017313 [TBL] [Abstract][Full Text] [Related]
3. Renal thrombotic microangiopathy and podocytopathy associated with the use of carfilzomib in a patient with multiple myeloma. Hobeika L; Self SE; Velez JC BMC Nephrol; 2014 Sep; 15():156. PubMed ID: 25267524 [TBL] [Abstract][Full Text] [Related]
4. Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition. Catanese L; Link K; Rupprecht H BMC Nephrol; 2023 Jun; 24(1):179. PubMed ID: 37337151 [TBL] [Abstract][Full Text] [Related]
8. Carfilzomib-induced hemolysis is noticeably common but rarely shows features of thrombotic microangiopathy: A retrospective study. Kozlowski P; Kameran Behnam K; Uggla B; Åström M Eur J Haematol; 2020 Jun; 104(6):588-593. PubMed ID: 32115785 [TBL] [Abstract][Full Text] [Related]
9. A review of thrombotic microangiopathies in multiple myeloma. Portuguese AJ; Gleber C; Passero FC; Lipe B Leuk Res; 2019 Oct; 85():106195. PubMed ID: 31404728 [TBL] [Abstract][Full Text] [Related]
10. Drug-induced Thrombotic Microangiopathy with Concurrent Proteasome Inhibitor Use in the Treatment of Multiple Myeloma: A Case Series and Review of the Literature. Monteith BE; Venner CP; Reece DE; Kew AK; Lalancette M; Garland JS; Shepherd LE; Pater JL; Hay AE Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e791-e800. PubMed ID: 32807717 [TBL] [Abstract][Full Text] [Related]
11. Clinical features, treatment, and outcomes of patients with carfilzomib induced thrombotic microangiopathy. Fang W; Sun W; Fang W; Zhao S; Wang C Int Immunopharmacol; 2024 Jun; 134():112178. PubMed ID: 38728883 [TBL] [Abstract][Full Text] [Related]
12. Renal thrombotic microangiopathy in a patient with septic disseminated intravascular coagulation. Sakamaki Y; Konishi K; Hayashi K; Hashiguchi A; Hayashi M; Kubota E; Saruta T; Itoh H BMC Nephrol; 2013 Nov; 14():260. PubMed ID: 24279773 [TBL] [Abstract][Full Text] [Related]
13. Carfilzomib-induced thrombotic microangiopathy. A case report. Scheggi V; Merilli I; Cesaroni E; Alterini B J Oncol Pharm Pract; 2022 Apr; 28(3):754-758. PubMed ID: 34904466 [TBL] [Abstract][Full Text] [Related]
14. Two cases of carfilzomib-induced thrombotic microangiopathy successfully treated with Eculizumab in multiple myeloma. Rassner M; Baur R; Wäsch R; Schiffer M; Schneider J; Mackensen A; Engelhardt M BMC Nephrol; 2021 Jan; 22(1):32. PubMed ID: 33461512 [TBL] [Abstract][Full Text] [Related]
15. Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative. Bendapudi PK; Li A; Hamdan A; Uhl L; Kaufman R; Stowell C; Dzik W; Makar RS Br J Haematol; 2015 Dec; 171(5):836-44. PubMed ID: 26314936 [TBL] [Abstract][Full Text] [Related]
16. Role of ADAMTS13 in the management of thrombotic microangiopathies including thrombotic thrombocytopenic purpura (TTP). Shah N; Rutherford C; Matevosyan K; Shen YM; Sarode R Br J Haematol; 2013 Nov; 163(4):514-9. PubMed ID: 24111495 [TBL] [Abstract][Full Text] [Related]